Literature DB >> 3403105

Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin.

D Acerbi1, C Bonati, G Boscarino, L Bufalino, F Cesari, E D'Ambrosio, P Mansanti, G Scali.   

Abstract

The age effect on the kinetics of piroxicam at the steady-state after oral administration of piroxicam beta-cyclodextrin was evaluated. The mean plasma concentration of piroxicam at the steady-state was significantly higher in elderly subjects (9.30 +/- 0.69 micrograms/ml mean +/- s.e.) than in younger adults (6.24 +/- 0.58 micrograms/ml mean +/- s.e.). Even though the distribution volume tended to be lower in elderly subjects (106.37 ml/kg), it did not show substantial differences in the two groups whereas the correlation between clearance and age was significant (p less than 0.05). It is therefore confirmed that piroxicam beta-cyclodextrin has the same pharmacokinetic behaviour at the steady-state in elderly subjects, as the active principle in a non-complexed form.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403105

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  3 in total

1.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.

Authors:  C R Lee; J A Balfour
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 3.  Piroxicam-β-cyclodextrin: a GI safer piroxicam.

Authors:  C Scarpignato
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.